Emerging Trends and Growth Drivers in the Neurogenic Detrusor Overactivity Market Through 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Does the Forecast Indicate for the Neurogenic Detrusor Overactivity Market From 2025 to 2029?
In recent years, the neurogenic detrusor overactivity market has experienced robust growth. The market is projected to expand from $1.69 billion in 2024 to $1.82 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.9%. This growth during the historical period can be accredited to factors such as the rising incidence of neurological disorders, increased awareness among medical professionals, widespread adoption of pharmaceutical therapies, growth in hospital and clinic networks, and higher diagnosis rates.
The market for neurogenic detrusor overactivity is projected to experience robust growth in the upcoming years. By 2029, the market size is anticipated to reach $2.45 billion, with a compound annual growth rate (CAGR) of 7.7%. The projected growth during the forecast period can be credited to factors such as an escalating elderly population, an increased occurrence of spinal cord injuries, upsurge in healthcare expenses, the rise of minimally invasive treatments, and enhanced patient knowledge and education. The forecast period will also see key trends like progress in stem cell techniques, innovations in drug delivery mechanisms, advancements in neuromodulation devices, research and the evolution of personalized medicine, and enhancements in minimally invasive procedures.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24619&type=smp
What Elements Are Contributing To Growth In The Neurogenic Detrusor Overactivity Market?
The neurogenic detrusor overactivity market is predicted to expand due to the increasing prevalence of neurological disorders. These medical conditions, which affect the brain, nerves, or spinal cord, can cause issues with movement, sensation, cognition, or other bodily functions. As people are living longer, the risk of neurological disorders, and thus age-related brain degeneration, is rising. Neurogenic detrusor overactivity (NDO) is a common bladder dysfunction associated with these disorders, including Parkinson’s disease, multiple sclerosis, and spinal cord injury. These conditions interfere with the normal nerve signals between the brain and bladder, causing involuntary bladder contractions. A 2024 study published by the American Academy of Neurology (AAN), a US-based neurology and neuroscience organization, anticipates there will be roughly 4.9 billion brain disorder cases worldwide by 2050, representing a 22% increase from around 4 billion cases in 2021. Hence, the increase in neurological disorders is fuelling the growth of the neurogenic detrusor overactivity market.
Which Segments Are Detailed In The Global Neurogenic Detrusor Overactivity Market Report?
The neurogenic detrusor overactivity market covered in this report is segmented –
1) By Types: Non-Surgical Treatment, Surgical Treatment, Follow-Up Treatment
2) By Application: Adult, Child
3) By End-User: Hospitals, Urology Clinics, Rehabilitation Centers, Private Practices, Long-Term Care Facilities
Subsegments:
1) By Non-Surgical Treatment: Antimuscarinic Drugs, Beta-3 Adrenergic Agonists, Behavioral Therapy, Neuromodulation, Clean Intermittent Catheterization, Intravesical Therapies
2) By Surgical Treatment: Botulinum Toxin Injection, Augmentation Cystoplasty, Urinary Diversion, External Sphincterotomy, Artificial Urinary Sphincter Implantation
3) By Follow-Up Treatment: Urodynamic Evaluation, Ultrasound Monitoring, Laboratory Tests, Ongoing Catheterization, Repeat Botulinum Toxin Injections, Patient and Caregiver Training, Quality of Life Assessment
Which Emerging Trends And Strategic Shifts Are Shaping The Neurogenic Detrusor Overactivity Market?
The central players in the neurogenic detrusor overactivity (NDO) treatment market are concentrating their efforts on the development of advanced generic treatments like beta-3 adrenergic receptor agonists, aiming to provide effective bladder control solutions at a lower cost. Agents like mirabegron work by relaxing the detrusor muscle in the bladder, which increases its capacity and reduces troubling symptoms such as urgency and incontinence. In April 2024, the India-based pharmaceutical firm, Lupin Ltd., was granted approval by the U.S. Food and Drug Administration (USFDA) to introduce Mirabegron, a generic version of Myrbetriq, to the U.S market. Mirabegron, an innovative once-daily oral therapy, provides a practical and effective treatment solution for overactive bladder (OAB) and neurogenic detrusor overactivity (NDO) patients, specifically in pediatric populations. This approval underlines Lupin’s objective of broadening the availability of high-quality, affordable generics in crucial therapeutic areas.
Who Are The Key Contributors To Growth In The Neurogenic Detrusor Overactivity Market?
Major companies operating in the neurogenic detrusor overactivity market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S. A., Medtronic plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries, Apotex Inc., Viatris Inc., Sumitomo Pharma America Inc., Galderma, Ipsen, Coloplast A/S, Aurobindo Pharma Limited, Hisamitsu Pharmaceutical Co. Inc., Kaken Pharmaceutical Co. Ltd., Hugel Inc.
Get The Full Report Here:
Which Region Is Projected To Lead The Neurogenic Detrusor Overactivity Market By 2025?
North America was the largest region in the neurogenic detrusor overactivity market in 2024. The regions covered in the neurogenic detrusor overactivity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24619&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
